Treat-to-target: LLDAS, DORIS remission, and flare prevention strategies

Clicks: 11
ID: 329560
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #319 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The goal of care in any medical condition is to optimise a person's current health status, with a view to positively impacting on their long-term outcomes. Since 2014 the concept of treat-to-target (T2T) in systemic lupus erythematosus (SLE) has been in development, enabled by a paradigm shift to focus on attainable treatment targets allowing for the development, validation, and adoption of a T2T approach. In this review, the history of this paradigm change will be reviewed, along with evidence from clinical trials that show increasing likelihood of achievement of these goals with more effective treatments and the associated benefit of reduced corticosteroid burden.
Reference Key
openalex_W7214074356 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Eric Francis Morand, Vera Golder, Rangi Kandane‐Rathnayake
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag460
URL
https://doi.org/10.1093/rheumatology/keag460
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.